Mar, Jordan S.
Ota, Naruhisa
Pokorzynski, Nick D.
Peng, Yutian
Jaochico, Allan
Sangaraju, Dewakar
Skippington, Elizabeth
Lekkerkerker, Annemarie N.
Rothenberg, Michael E.
Tan, Man-Wah
Yi, Tangsheng
Keir, Mary E.
Article History
Received: 24 August 2022
Accepted: 1 February 2023
First Online: 9 March 2023
Declarations
:
: The Ph1B study briefly described in this manuscript (NCT02749630) was conducted in full conformance with the International Council for Harmonization (ICH) E6 guideline for Good Clinical Practice and the Principles of the Declaration of Helsinki or the laws and regulations of the country where the research was conducted, whichever afforded the greater protection to the individual. The study complied with the requirements of the ICH E2A guideline. Studies conducted in the European Union/European Economic Area complied with the E.U. Clinical Trial Directive (2001/20/EC). The protocol was approved by an Institutional Review Board (IRB) before the study was initiated. All participants provided written informed consent. All animal experiments were approved by the Genentech Institutional Animal Care and Use Committee.
: Not applicable.
: JSM, NO, YP, AJ, DS, ES, ANL, MR, MWT, and MK are employees of Genentech, Inc. NDP and TY are former employees of Genentech, Inc.